Cytosorbents (NASDAQ:CTSO) Share Price Crosses Above 200 Day Moving Average - What's Next?

Shares of Cytosorbents Co. (NASDAQ:CTSO - Get Free Report) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.99 and traded as high as $1.10. Cytosorbents shares last traded at $1.07, with a volume of 23,276 shares trading hands.

Analyst Ratings Changes

A number of brokerages have recently issued reports on CTSO. HC Wainwright reissued a "neutral" rating and set a $1.00 price objective on shares of Cytosorbents in a research report on Thursday, May 15th. Wall Street Zen assumed coverage on shares of Cytosorbents in a research note on Wednesday, May 21st. They set a "hold" rating on the stock. Finally, D. Boral Capital restated a "buy" rating and set a $10.00 target price on shares of Cytosorbents in a research note on Thursday, May 15th.

Cytosorbents Stock Performance

The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. The business's 50 day moving average is $0.97 and its two-hundred day moving average is $1.00. The company has a market cap of $76.38 million, a PE ratio of -3.39 and a beta of 1.05.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last released its earnings results on Wednesday, May 14th. The medical research company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02. The company had revenue of $8.73 million for the quarter, compared to analysts' expectations of $9.01 million. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. On average, equities research analysts anticipate that Cytosorbents Co. will post -0.3 EPS for the current year.

Institutional Trading of Cytosorbents

Several hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its stake in Cytosorbents by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock worth $80,000 after purchasing an additional 8,400 shares in the last quarter. Northern Trust Corp lifted its stake in Cytosorbents by 22.3% in the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock worth $83,000 after purchasing an additional 16,701 shares in the last quarter. Skylands Capital LLC increased its holdings in shares of Cytosorbents by 1.0% in the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company's stock worth $2,531,000 after buying an additional 26,195 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Cytosorbents in the 4th quarter worth about $30,000. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Cytosorbents by 149.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company's stock worth $63,000 after buying an additional 37,519 shares during the last quarter. Hedge funds and other institutional investors own 32.87% of the company's stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.